B-cell depletion with rituximab in the treatment of autoimmune diseases

Bibliography

• REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435-445.
   PubMed Web of Science ®Google Scholar
• BOYE J, ELTER T, ENGERT A: An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. (2003) 14:520-535.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, CAMBRIDGE G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 40:205-211.
   PubMed Web of Science ®Google Scholar
• COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. (2006) 54:2793-2806.
   PubMed Web of Science ®Google Scholar
• EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSKA A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. (2006) 54:1390-1400.
   PubMed Web of Science ®Google Scholar
• COOPER N, STASI R, CUNNINGHAM-RUNDLES S et al.: The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. (2004) 125:232-239.
   PubMed Web of Science ®Google Scholar
• ARNOLD DM, DENTALI F, CROWTHER MA et al.: Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. (2007) 146:25-33.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50:2580-2589.
   PubMed Web of Science ®Google Scholar
• VALLERSKOG T, GUNNARSSON I, WIDHE M et al.: Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. (2007) 122:62-74.
   PubMed Web of Science ®Google Scholar
• KEOGH KA, YTTERBERG SR, FERVENZA FC, CARLSON KA, SCHROEDER DR, SPECKS U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. (2006) 173:180-187.
   PubMed Web of Science ®Google Scholar
• STASI R, STIPA E, DEL POETA G, AMADORI S, NEWLAND AC, PROVAN D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) (2006) 45:1432-1436.
   PubMed Web of Science ®Google Scholar
• PIJPE J, VAN IMHOFF GW, SPIJKERVET FK et al.: Rituximab treatment in patients with primary Sjogren's syndrome: an open-label Phase II study. Arthritis Rheum. (2005) 52:2740-2750.
   PubMed Web of Science ®Google Scholar
• HAIN B, JORDAN K, DESCHAUER M, ZIERZ S: Successful treatment of musk antibody-positive myasthenia gravis with rituximab. Muscle Nerve (2006) 33:575-580.
   PubMed Web of Science ®Google Scholar
• KONG HH, PROSE NS, WARE RE, HALL RP III: Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr. Dermato. (2005) 22:461-464.
   PubMed Web of Science ®Google Scholar
• STASI R, BRUNETTI M, STIPA E, AMADORI S: Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood (2004) 103:4424-4428.
   PubMed Web of Science ®Google Scholar
• GEORGE JN, WOODSON RD, KISS JE, KOJOURI K, VESELY SK: Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J. Clin. Apher. (2006) 21:49-56.
   PubMed Web of Science ®Google Scholar
• EL FASSI D, NIELSEN CH, BONNEMA SJ, HASSELBALCH HC, HEGEDüS L: B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J. Clin. Endocrinol. Metab. (2007) 92(5):1769-1772.
   PubMed Web of Science ®Google Scholar
• EL FASSI D, NIELSEN CH, HASSELBALCH HC, HEGEDüS L: Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid (2006) 16:709-710.
   PubMed Web of Science ®Google Scholar
• SALVI M, VANNUCCHI G, CAMPI I et al.: Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol. (2006) 154:511-517.
   PubMed Web of Science ®Google Scholar
• SALVI M, VANNUCCHI G, CAMPI I et al.: Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. (2007) 156:33-40.
   PubMed Web of Science ®Google Scholar
• LOKEN MR, SHAH VO, DATTILIO KL, CIVIN CI: Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood (1987) 70:1316-1324.
   PubMed Web of Science ®Google Scholar
• STASHENKO P, NADLER LM, HARDY R, SCHLOSSMAN SF: Characterization of a human B lymphocyte-specific antigen. J. Immunol. (1980) 125:1678-1685.
   PubMed Web of Science ®Google Scholar
• DWORZAK MN, FRITSCH G, FLEISCHER C et al.: Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia (1997) 11:1266-1273.
   PubMed Web of Science ®Google Scholar
• MCKENNA RW, WASHINGTON LT, AQUINO DB, PICKER LJ, KROFT SH: Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood (2001) 98:2498-2507.
   PubMed Web of Science ®Google Scholar
• LUCIO P, PARREIRA A, VAN DEN BEEMD MW et al.: Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia (1999) 13:419-427.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, CAMBRIDGE G, EHRENSTEIN MR, EDWARDS JC: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. (2006) 54:613-620.
   PubMed Web of Science ®Google Scholar
• BUBIEN JK, ZHOU LJ, BELL PD, FRIZZELL RA, TEDDER TF: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. (1993) 121:1121-1132.
   PubMed Web of Science ®Google Scholar
• TEDDER TF, BOYD AW, FREEDMAN AS, NADLER LM, SCHLOSSMAN SF: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J. Immunol. (1985) 135:973-979.
   PubMed Web of Science ®Google Scholar
• UCHIDA J, LEE Y, HASEGAWA M et al.: Mouse CD20 expression and function. Int. Immunol. (2004) 16:119-129.
   PubMed Web of Science ®Google Scholar
• DYKSTRA ML, CHERUKURI A, PIERCE SK: Floating the raft hypothesis for immune receptors: access to rafts controls receptor signaling and trafficking. Traffic (2001) 2:160-166.
   PubMed Web of Science ®Google Scholar
• JANAS E, PRIEST R, WILDE JI, WHITE JH, MALHOTRA R: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. (2005) 139:439-446.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, CAMPBELL D, FELGAR RE et al.: The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48:455-459.
   PubMed Web of Science ®Google Scholar
• GORTER A, MERI S: Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today (1999) 20:576-582.
   PubMedGoogle Scholar
• HARJUNPAA A, JUNNIKKALA S, MERI S: Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. (2000) 51:634-641.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, CAMBRIDGE G: Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) (2005) 44:151-156.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, BARNARD J, CAPPIONE A et al.: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. (2004) 50:3580-3590.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, EDWARDS JC, CAMBRIDGE G: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. (2002) 61:883-888.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA K, Hardy RR: Development and function of B-1 cells. Curr. Opin. Immunol. (2000) 12:346-353.
   PubMed Web of Science ®Google Scholar
• KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology (2002) 206:519-527.
   PubMed Web of Science ®Google Scholar
• BOHM I: Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed. Pharmacother. (2004) 58:338-343.
   PubMed Web of Science ®Google Scholar
• ROUZIERE AS, KNEITZ C, PALANICHAMY A, DORNER T, TONY HP: Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res. Ther. (2005) 7:R714-R724.
   PubMedGoogle Scholar
• PUGH-Bernard AE, SILVERMAN GJ, CAPPIONE AJ et al.: Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. (2001) 108:1061-1070.
   PubMed Web of Science ®Google Scholar
• ALWAYN IPJ, XU YX, BASKER M et al.: Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20-and CD22-positive B cells does not result in significantly decreased production of anti-α Gal antibody. Xenotransplantation (2001) 8:157-171.
   PubMed Web of Science ®Google Scholar
• SCHRODER C, AZIMZADEH AM, WU G, PRICE JO, ATKINSON JB, PIERSON RN: Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl. Immunol. (2003) 12:19-28.
   PubMed Web of Science ®Google Scholar
• HANSEN S, LESLIE RG: TGN-1412: scrutinizing preclinical trials of antibody-based medicines. Nature (2006) 441:282.
   PubMed Web of Science ®Google Scholar
• GONG Q, OU Q, YE S et al.: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. (2005) 174:817-826.
   PubMed Web of Science ®Google Scholar
• PARAN D, TREJ'O L, CASPI D: Clinical images: B cell depletion in the appendix following rituximab treatment. Arthritis Rheum. (2006) 54:2151.
   PubMedGoogle Scholar
• LEANDRO MJ, COOPER N, CAMBRIDGE G, EHRENSTEIN MR, EDWARDS JC: Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) (2007) 46:29-36.
   PubMed Web of Science ®Google Scholar
• JILANI I, O'BRIEN S, MANSHURI T et al.: Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood (2003) 102:3514-3520.
   PubMed Web of Science ®Google Scholar
• SFIKAKIS PP, BOLETIS JN, LIONAKI S et al.: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. (2005) 52:501-513.
   PubMed Web of Science ®Google Scholar
• SFIKAKIS PP, SOULIOTIS VL, FRAGIADAKI KG, MOUTSOPOULOS HM, BOLETIS JN, THEOFILOPOULOS AN: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. (2007) 123:66-73.
   PubMed Web of Science ®Google Scholar
• SEDDON B, MASON D: Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor β and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC(-) cells and CD4(+)CD8(-) thymocytes. J. Exp. Med. (1999) 189:279-288.
   PubMed Web of Science ®Google Scholar
• VIGNA-Perez M, HERNANDEZ-CASTRO B, PAREDES-SAHAROPULOS O et al.: Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. (2006) 8:R83.
   PubMed Web of Science ®Google Scholar
• TOUBI E, KESSEL A, SLOBODIN G et al.: Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) (In Press).
   PubMedGoogle Scholar
• LEVINE TD, PESTRONK A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology (1999) 52:1701-1704.
   PubMed Web of Science ®Google Scholar
• ARBUCKLE MR, MCCLAIN MT, RUBERTONE MV et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. (2003) 349:1526-1533.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46:2673-2677.
   PubMed Web of Science ®Google Scholar
• SABAHI R, ANOLIK JH: B-cell-targeted therapy for systemic lupus erythematosus. Drugs (2006) 66:1933-1948.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA M, SAITO K, KAWABATA D et al.: Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. (2006) 66:470-475.
   PubMed Web of Science ®Google Scholar
• VAN Vollenhoven RF, GUNNARSSON I, WELIN-HENRIKSSON E et al.: Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol. (2004) 33:423-427.
   PubMed Web of Science ®Google Scholar
• SMITH KG, JONES RB, BURNS SM, JAYNE DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. (2006) 54:2970-2982.
   PubMed Web of Science ®Google Scholar
• MANDERSON AP, BOTTO M, WALPORT MJ: The role of complement in the development of systemic lupus erythematosus. Ann. Rev. Immunol. (2004) 22:431-456.
   PubMed Web of Science ®Google Scholar
• CINES DB, BLANCHETTE VS: Immune thrombocytopenic purpura. N. Engl. J. Med. (2002) 346:995-1008.
   PubMed Web of Science ®Google Scholar
• EL FASSI D, NIELSEN CH, HASSELBALCH HC, HEGEDüS L: The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol. (2006) 154:623-632.
   PubMed Web of Science ®Google Scholar
• HASSELBALCH HC: B-cell depletion with rituximab-a targeted therapy for Graves’ disease and autoimmune thyroiditis. Immunol. Lett. (2003) 88:85-86.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, CAMBRIDGE G, ABRAHAMS VM: Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology (1999) 97:188-196.
   PubMed Web of Science ®Google Scholar
• ABRAHAMS VM, CAMBRIDGE G, LYDYARD PM, EDWARDS JC: Induction of tumor necrosis factor α production by adhered human monocytes: a key role for Fcγ receptor Type IIIa in rheumatoid arthritis. Arthritis Rheum. (2000) 43:608-616.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350:2572-2581.
   PubMed Web of Science ®Google Scholar
• POPA C, LEANDRO MJ, CAMBRIDGE G, EDWARDS JC: Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology (Oxford) (2006) 46:626-630.
   PubMed Web of Science ®Google Scholar
• DASS S, VITAL EM, EMERY P: Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. (2006) 7:2559-2570.
   PubMed Web of Science ®Google Scholar
• WEETMAN AP: Graves’ disease. N. Engl. J. Med. (2000) 343:1236-1248.
   PubMed Web of Science ®Google Scholar
• ZAKARIJA M, MCKENZIE JM, MUNRO DS: Immunoglobulin G inhibitor of thyroid-stimulating antibody is a cause of delay in the onset of neonatal Graves’ disease. J. Clin. Invest. (1983) 72:1352-1356.
   PubMed Web of Science ®Google Scholar
• ASMAN P: Ophthalmological evaluation in thyroid-associated ophthalmopathy. Acta Ophthalmol. Scand. (2003) 81:437-448.
   PubMedGoogle Scholar
• WEETMAN AP, MCGREGOR AM, WHEELER MH, HALL R: Extrathyroidal sites of autoantibody synthesis in Graves’ disease. Clin. Exp. Immunol. (1984) 56:330-336.
   PubMed Web of Science ®Google Scholar
• CHIOVATO L, LATROFA F, BRAVERMAN LE et al.: Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. (2003) 139:346-351.
   PubMed Web of Science ®Google Scholar
• SMITH TJ, BAHN RS, GORMAN CA: Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr. Rev. (1989) 10:366-391.
   PubMed Web of Science ®Google Scholar
• SMITH TJ, WANG HS, EVANS CH: Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am. J. Physiol. (1995) 268:C382-C388.
   PubMed Web of Science ®Google Scholar
• WANG HS, CAO HJ, WINN VD et al.: Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J. Biol. Chem. (1996) 271:22718-22728.
   PubMed Web of Science ®Google Scholar
• YOUNG DA, EVANS CH, SMITH TJ: Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc. Natl. Acad. Sci. USA (1998) 95:8904-8909.
   PubMed Web of Science ®Google Scholar
• WEGROWSKI J, BELLON G, HAYE B, BOREL JP: Effects of thyroid-stimulating hormone and phorbol ester on glycosaminoglycan synthesis in porcine thyroid epithelial cells in primary culture. Cell Biol. Int. Rep. (1989) 13:881-890.
   PubMedGoogle Scholar
• ROTELLA CM, ZONEFRATI R, TOCCAFONDI R, VALENTE WA, KOHN LD: Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves’ sera. J. Clin. Endocrinol. Metab. (1986) 62:357-367.
   PubMed Web of Science ®Google Scholar
• GOPINATH B, MUSSELMAN R, ADAMS CL, TANI J, BEARD N, WALL JR: Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with graves’ disease with and without ophthalmopathy: correlation with clinical features. Thyroid (2006) 16:967-974.
   PubMed Web of Science ®Google Scholar
• SMITH TJ, HOA N: Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J. Clin. Endocrinol. Metab. (2004) 89:5076-5080.
   PubMed Web of Science ®Google Scholar
• YAMADA M, LI AW, WEST KA, CHANG CH, WALL JR: Experimental model for ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the thyrotropin receptor. Autoimmunity (2002) 35:403-413.
   PubMed Web of Science ®Google Scholar
• COOPER DS: Antithyroid drugs. N. Engl. J. Med. (2005) 352:905-917.
   PubMed Web of Science ®Google Scholar
• MANCA F, FENOGLIO D, LI PG, KUNKL A, CELADA F: Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med. (1991) 173:37-48.
   PubMed Web of Science ®Google Scholar
• GETAHUN A, DAHLSTROM J, WERNERSSON S, HEYMAN B: IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc γ receptors. J. Immunol. (2004) 172:5269-5276.
   PubMed Web of Science ®Google Scholar
• CAMBRIDGE G, LEANDRO MJ, TEODORESCU M et al.: B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. (2006) 54:3612-3622.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus – a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50:2580-2589.
   PubMed Web of Science ®Google Scholar
• GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. (2005) 64:913-920.
   PubMed Web of Science ®Google Scholar
• RING T, KALLENBACH M, PRAETORIUS J, NIELSEN S, MELGAARD B: Successful treatment of a patient with primary Sjogren's syndrome with rituximab. Clin. Rheumatol. (2006) 25:891-894.
   PubMed Web of Science ®Google Scholar
• MOSER K, MUEHLINGHAUS G, MANZ R et al.: Long-lived plasma cells in immunity and immunopathology. Immunol. Lett. (2006) 103:83-85.
   PubMed Web of Science ®Google Scholar
• LANZAVECCHIA A: Antigen-specific interaction between T and B cells. Nature (1985) 314:537-539.
   PubMed Web of Science ®Google Scholar
• YANG X, BRUNHAM RC: Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J. Immunol. (1998) 161:1439-1446.
   PubMed Web of Science ®Google Scholar
• VORDERMEIER HM, VENKATAPRASAD N, HARRIS DP, IVANYI J: Increase of tuberculous infection in the organs of B cell-deficient mice. Clin. Exp. Immunol. (1996) 106:312-316.
   PubMed Web of Science ®Google Scholar
• MATSUZAKI G, VORDERMEIER HM, HASHIMOTO A, NOMOTO K, IVANYI J: The role of B cells in the establishment of T cell response in mice infected with an intracellular bacteria, Listeria monocytogenes. Cell Immunol. (1999) 194:178-185.
   PubMed Web of Science ®Google Scholar
• CRAWFORD A, MACLEOD M, SCHUMACHER T, CORLETT L, GRAY D: Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. (2006) 176:3498-3506.
   PubMed Web of Science ®Google Scholar
• CONSTANT S, SANT'ANGELO D, PASQUALINI T et al.: Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. J. Immunol. (1995) 154:4915-4923.
   PubMed Web of Science ®Google Scholar
• HARADA M, MAKINO S: Suppression of overt diabetes in NOD mice by anti-thymocyte serum or anti-Thy 1, 2 antibody. Jikken Dobutsu (1986) 35:501-504.
   PubMed Web of Science ®Google Scholar
• KOIKE T, ITOH Y, ISHII T et al.: Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes (1987) 36:539-541.
   PubMed Web of Science ®Google Scholar
• BENDELAC A, CARNAUD C, BOITARD C, BACH JF: Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J. Exp. Med. (1987) 166:823-832.
   PubMed Web of Science ®Google Scholar
• HASKINS K, MCDUFFIE M: Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science (1990) 249:1433-1436.
   PubMed Web of Science ®Google Scholar
• SERREZE DV, CHAPMAN HD, VARNUM DS et al.: B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new ‘speed congenic’ stock of NOD.Igμ null mice. J. Exp. Med. (1996) 184:2049-2053.
   PubMed Web of Science ®Google Scholar
• AKASHI T, NAGAFUCHI S, ANZAI K et al.: Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice. Int. Immunol. (1997) 9:1159-1164.
   PubMed Web of Science ®Google Scholar
• SERREZE DV, FLEMING SA, CHAPMAN HD, RICHARD SD, LEITER EH, TISCH RM: B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. (1998) 161:3912-3918.
   PubMed Web of Science ®Google Scholar
• TAKEMURA S, KLIMIUK PA, BRAUN A, GORONZY JJ, WEYAND CM: T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. (2001) 167:4710-4718.
   PubMed Web of Science ®Google Scholar
• CHAN OT, HANNUM LG, HABERMAN AM, MADAIO MP, SHLOMCHIK MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. (1999) 189:1639-1648.
   PubMed Web of Science ®Google Scholar
• GUO J, WANG Y, RAPOPORT B, MCLACHLAN SM: Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts co-expressing TPO and MHC class II. Clin. Exp. Immunol. (2000) 119:38-46.
   PubMed Web of Science ®Google Scholar
• PICHURIN P, ALIESKY H, CHEN CR, NAGAYAMA Y, RAPOPORT B, MCLACHLAN SM: Thyrotrophin receptor-specific memory T cell responses require normal B cells in a murine model of Graves’ disease. Clin. Exp. Immunol. (2003) 134:396-402.
   PubMed Web of Science ®Google Scholar
• BRALEY-MULLEN H, YU S: Early requirement for B cells for development of spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. (2000) 165:7262-7269.
   PubMed Web of Science ®Google Scholar
• STORCH MK, PIDDLESDEN S, HALTIA M, IIVANAINEN M, MORGAN P, LASSMANN H: Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. (1998) 43:465-471.
   PubMed Web of Science ®Google Scholar
• TRAN GT, HODGKINSON SJ, CARTER N, KILLINGSWORTH M, SPICER ST, HALL BM: Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J. Immunol. (2002) 168:4293-4300.
   PubMed Web of Science ®Google Scholar
• SOSPEDRA M, MARTIN R: Immunology of multiple sclerosis. Ann. Rev. Immunol. (2005) 23:683-747.
   PubMed Web of Science ®Google Scholar
• BERGER T, RUBNER P, SCHAUTZER F et al.: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. (2003) 349:139-145.
   PubMed Web of Science ®Google Scholar
• GIANANI R, EISENBARTH GS: The stages of Type 1A diabetes: 2005. Immunol. Rev. (2005) 204:232-249.
   PubMed Web of Science ®Google Scholar
• NIELSEN CH, LESLIE RG, JEPSEN BS, KAZATCHKINE MD, KAVERI SV, FISCHER E: Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur. J. Immunol. (2001) 31:2660-2668.
   PubMed Web of Science ®Google Scholar
• NIELSEN CH, HEGEDüS L, LESLIE RG: Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur. J. Immunol. (2004) 34:263-272.
   PubMed Web of Science ®Google Scholar
• THORNTON BP, VETVICKA V, ROSS GD: Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J. Immunol. (1994) 152:1727-1737.
   PubMed Web of Science ®Google Scholar
• THORNTON BP, VETVICKA V, ROSS GD: Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Clin. Exp. Immunol. (1996) 104:531-537.
   PubMed Web of Science ®Google Scholar
• NIELSEN CH, LESLIE RG: Complement's participation in acquired immunity. J. Leukoc. Biol. (2002) 72:249-261.
   PubMed Web of Science ®Google Scholar
• ARVIEUX J, YSSEL H, COLOMB MG: Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology (1988) 65:229-235.
   PubMed Web of Science ®Google Scholar
• JACQUIER-SARLIN MR, GABERT FM, VILLIERS MB, COLOMB MG: Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology (1995) 84:164-170.
   PubMed Web of Science ®Google Scholar
• BOACKLE SA, MORRIS MA, HOLERS VM, KARP DR: Complement opsonization is required for presentation of immune complexes by resting peripheral blood B cells. J. Immunol. (1998) 161:6537-6543.
   PubMed Web of Science ®Google Scholar
• KORB LC, AHEARN JM: C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J. Immunol. (1997) 158:4525-4528.
   PubMed Web of Science ®Google Scholar
• OCHSENBEIN AF, FEHR T, LUTZ C et al.: Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 286:2156-2159.
   PubMed Web of Science ®Google Scholar
• KIMBY E: Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. (2005) 31:456-473.
   PubMed Web of Science ®Google Scholar
• JENSEN M, WINKLER U, MANZKE O, DIEHL V, ENGERT A: Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann. Hematol. (1998) 77:89-91.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ A, RODRIGUEZ J, MARTINEZ J et al.: Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma. Leuk. Lymphoma (2006) 47:111-115.
   PubMed Web of Science ®Google Scholar
• BENDTZEN K, GEBOREK P, SVENSON M, LARSSON L, KAPETANOVIC MC, SAXNE T: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum. (2006) 54:3782-3789.
   PubMed Web of Science ®Google Scholar
• ANDERSON D, BISHOP JB, GARNER RC, OSTROSKY-WEGMAN P, SELBY PB: Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat. Res. (1995) 330:115-181.
   PubMed Web of Science ®Google Scholar
• SMELAND EB, BLOMHOFF HK, FUNDERUD S, SHALABY MR, ESPEVIK T: Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J. Exp. Med. (1989) 170:1463-1468.
   PubMed Web of Science ®Google Scholar
• FILLATREAU S, SWEENIE CH, MCGEACHY MJ, GRAY D, ANDERTON SM: B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. (2002) 3:944-950.
   PubMed Web of Science ®Google Scholar
• MAURI C, GRAY D, MUSHTAQ N, LONDEI M: Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. (2003) 197:489-501.
   PubMed Web of Science ®Google Scholar
• PAREKH VV, PRASAD DV, BANERJEE PP, JOSHI BN, KUMAR A, MISHRA GC: B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-β 1. J. Immunol. (2003) 170:5897-5911.
   PubMed Web of Science ®Google Scholar
• BENNETT SR, CARBONE FR, TOY T, MILLER JF, HEATH WR: B cells directly tolerize CD8(+) T cells. J. Exp. Med. (1998) 188:1977-1983.
   PubMed Web of Science ®Google Scholar
• SKOK J, POUDRIER J, GRAY D: Dendritic cell-derived IL-12 promotes B cell induction of TH2 differentiation: a feedback regulation of TH1 development. J. Immunol. (1999) 163:4284-4291.
   PubMed Web of Science ®Google Scholar
• BOURKE E, BOSISIO D, GOLAY J, POLENTARUTTI N, MANTOVANI A: The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood (2003) 102:956-963.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN SR, KASHGARIAN M, ALEXOPOULOU L, FLAVELL RA, AKIRA S, SHLOMCHIK MJ: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. (2005) 202:321-331.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN SR, SHUPE J, NICKERSON K, KASHGARIAN M, FLAVELL RA, SHLOMCHIK MJ: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 25:417-428.
   PubMed Web of Science ®Google Scholar
• CARELLA C, MAZZIOTTI G, SORVILLO F et al.: Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid (2006) 16:295-302.
   PubMed Web of Science ®Google Scholar
• BROWNING JL: B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. (2006) 5:564-576.
   PubMed Web of Science ®Google Scholar
• GILBERT JA, KALLED SL, MOORHEAD J et al.: Treatment of autoimmune hyperthyroidism in a murine model of Graves’ disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology (2006) 147:4561-4568.
   PubMed Web of Science ®Google Scholar
• CAWOOD T, MORIARTY P, O'SHEA D: Recent developments in thyroid eye disease. Br. Med. J. (2004) 329:385-390.
   PubMed Web of Science ®Google Scholar
• EL Fassi D, NIELSEN CH, BENDTZEN K: Rituximab (MabThera) as treatment of active rheumatoid arthritis. Ugeskr. Laeger (2006) 168:4079-4081.
   PubMedGoogle Scholar